Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.32 |
| ▸ | BLM | P54132 | 3/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770925 | 0.86 | FAAH (0.35) | KMT2AMEN1RCE1TP53CYP1A2 | |
| SCHEMBL755487 | 0.85 | KMT2A (0.39) | KMT2AMEN1RCE1CYP1A2CYP2C19 | |
| SCHEMBL18506464 | 0.81 | ALDH1A1 (0.36) | KMT2AMEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL23841160 | 0.79 | SPHK2 (0.36) | KMT2AMEN1RCE1 | |
| Succinamide SCHEMBL36057 | 0.74 | — | — | |
| Succinamide SCHEMBL28157588 | 0.74 | LMNA (0.50) | KMT2AMEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL3127925 | 0.74 | KMT2A (0.35) | KMT2AMEN1RCE1TP53CYP1A2 | |
| SCHEMBL3628615 | 0.74 | ALDH1A1 (0.59) | KMT2ALMNAALDH1A1TDP1 | |
| SCHEMBL11253721 | 0.74 | ALDH1A1 (0.35) | KMT2AALDH1A1 | |
| SCHEMBL409946 | 0.74 | EGLN1 (0.53) | KMT2ACYP2C19PMP22LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2019050850-A1 | BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS AND METHODS OF PREPARATION AND USE THEREOF | PRIMETIME LIFE SCIENCES, LLC (US) | 2019-03-14 | — | — | WO | disclosed |
| US-10030004-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160326137-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2016-11-10 | — | — | US | disclosed |
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | ALLACCEM, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| EP-0765879-B1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO CO (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| EP-0765879-A1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO COMPANY LIMITED (JP) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GRIN1, GRIN3A, GRIN2C | KMT2A 394/4885MEN1 2143/4885RCE1 3706/4885 |
| US-10030004-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | KMT2A 2362/4885MEN1 1785/4885RCE1 1495/4885 |
| US-20130040924-A1 | BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR THE INHIBITION AND AMELIORATION OF DISEASE | PKD1, VHL, PKD2 | KMT2A 2822/4885MEN1 552/4885RCE1 499/4885 |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | KMT2A 4287/4885MEN1 4869/4885RCE1 204/4885 |
| US-20160326137-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | KMT2A 2362/4885MEN1 1785/4885RCE1 1495/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | KMT2A 4117/4885MEN1 4860/4885RCE1 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.